SUPN Supernus Pharmaceuticals Inc

$44.90

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/18/2025

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.

Website: https://www.supernus.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1356576
Address
1550 E GUDE DR, ROCKVILLE, MD, US
Valuation
Market Cap
$1.72B
P/E Ratio
23.30
PEG Ratio
1.47
Price to Book
1.66
Performance
EPS
$1.32
Dividend Yield
—
Profit Margin
11.20%
ROE
7.55%
Technicals
50D MA
$33.19
200D MA
$33.81
52W High
$40.28
52W Low
$25.53
Fundamentals
Shares Outstanding
56M
Target Price
$38.80
Beta
0.90

SUPN EPS Estimates vs Actual

● Estimated
● Actual

SUPN News & Sentiment

Nov 18, 2025 • Motley Fool SOMEWHAT-BULLISH
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally
A healthcare hedge fund just locked in gains on one of its biggest winners-here's what that move really signals.
Nov 04, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Supernus Pharmaceuticals ( SUPN ) Surpasses Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +23.17% and +5.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Oct 30, 2025 • Zacks Commentary NEUTRAL
Analysts Estimate Amphastar Pharmaceuticals ( AMPH ) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 29, 2025 • Zacks Commentary NEUTRAL
BridgeBio Pharma ( BBIO ) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -7.95% and +14.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 29, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Here's Why Supernus Pharmaceuticals ( SUPN ) is a Great Momentum Stock to Buy
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sentiment Snapshot

Average Sentiment Score:

0.206
50 articles with scored sentiment

Overall Sentiment:

Bullish

SUPN Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Pre market)
-0.08 Surprise
  • Reported EPS: $0.40
  • Estimate: $0.48
  • Whisper: —
  • Surprise %: -16.7%
May 06, 2025
Mar 31, 2025 (Pre market)
0.06 Surprise
  • Reported EPS: $0.44
  • Estimate: $0.38
  • Whisper: —
  • Surprise %: 14.8%
Feb 25, 2025
Dec 31, 2024 (Pre market)
0.03 Surprise
  • Reported EPS: $0.55
  • Estimate: $0.52
  • Whisper: —
  • Surprise %: 5.4%
Nov 04, 2024
Sep 30, 2024 (Post market)
0.25 Surprise
  • Reported EPS: $0.69
  • Estimate: $0.44
  • Whisper: —
  • Surprise %: 56.8%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.36
  • Estimate: $0.31
  • Whisper: —
  • Surprise %: 16.1%
May 08, 2024
Mar 31, 2024 (Post market)
-0.12 Surprise
  • Reported EPS: $0.26
  • Estimate: $0.38
  • Whisper: —
  • Surprise %: -31.6%
Feb 27, 2024
Dec 31, 2023 (Post market)
0.34 Surprise
  • Reported EPS: $0.89
  • Estimate: $0.55
  • Whisper: —
  • Surprise %: 61.8%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.16 Surprise
  • Reported EPS: $0.24
  • Estimate: $0.08
  • Whisper: —
  • Surprise %: 200.0%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.21 Surprise
  • Reported EPS: $-0.02
  • Estimate: $-0.23
  • Whisper: —
  • Surprise %: 91.3%

Financials